“We remain confident in our full-year performance as we believe we are well positioned to help address the expected rising need later in the year among older adults at increased risk for RSV.”

In context

“where we are rising to meet substantial demand. This product delivered strong results in the quarter with 44% year-over-year global operational revenue growth. We see additional opportunities for expanding share in both acute and prevention usage, as well as growth opportunities in international markets where we are making progress with our launches. I hope Alexandre will be able to touch based on this during the Q&A Session. Now, I will touch on a few additional product portfolio highlights. In the pediatric segment, Prevnar 20 continues to demonstrate strong performance that reinforces a leadership position among pneumococcal vaccines in the United States where market share grew to greater than 80%. During the quarter, the performance of Abrysvo was in line with seasonal vaccine trends. We remain confident in our full-year performance as we believe we are well positioned to help address the expected rising need later in the year among older adults at increased risk for RSV. Litfulo is a product we launched last year and we're encouraged by strong demand. Approximately one out of every two new patients on advanced systemic therapies is receiving a Litfulo prescription, a position we expect to grow as we continue focusing on execution. We view Velsipity as a promising and much-needed option for adults with moderate to severe active ulcerative colitis. We're encouraged by recently securing preferred coverage for Velsipity at our first large national payer. We expect to see the impact of this in 2025 and now we're working to build on this with additional payers. When we consider core products in our portfolio, we are also seeing positive impact from strong execution. The Vyndaqel family of products offers a good example of how we are making a difference for pati”